On March 3, 2026, Vera Therapeutics’ Compensation Committee awarded non-qualified stock options for 46,000 shares and RSUs for 25,875 shares to six new employees under the 2024 Inducement Plan, approved in accordance with Nasdaq Listing Rule 5635(c)(4). These grants serve as a material inducement for the hires’ employment agreements.

Each option carries a $39.30 per-share exercise price, matching the March 3 closing price, and vests over four years with a 25% cliff after one year followed by monthly vesting over 36 months. RSU awards vest in four equal annual installments on either February 20 or May 20, 2026, based on each employee’s start date.

If all awards fully vest and options are exercised, up to 71,875 new shares could enter circulation, creating modest dilution. Investors should track the timing of vesting and exercise behaviors to assess longer-term share count changes.